Characterization of Epithelial Ovarian Cancer Patients in Terms of Homologous Recombination Phenotype
Recruiting
Observational Study
Ovarian Cancer
Primary Peritoneal Cancer
Fallopian Tube Cancer
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 – 100
- Sex
- Female
- Study type
- Observational
- Participants needed
- 1,000 (estimated)
- Sponsor
- Nordic Society of Gynaecological Oncology - Clinical Trials Unit · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This is a prospective observational multi-country, multi-center study of a large real-world cohort of first line (1L) epithelial ovarian cancer patients, exposed to standard of care (SOC) treatment stratified according to BRCA1/2 and HRD status.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Patients are eligible to be included in the study, if all the following inclusion criteria are met:
* Patients with newly diagnosed histologically confirmed epithelial ovarian cancer:
* FIGO stage I-II with a known BRCA1/2 mutation (germline/gBRCA or somatic/tBRCA)
* FIGO stage III-IV of any h…
Contacts